Health Care

Analysts are expecting Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to achieve $16.30 Price Target

0 3

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) climbed +1.90% and ended at $9.14 greater than previous closing price of $8.97. The total 3.61 million shares were bought and sold throughout the most recent trading session more than average volume of 372.32 thousand shares.

Karyopharm Therapeutics Inc. (KPTI):

Currently Karyopharm Therapeutics Inc. (KPTI) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “7″ Analysts”. “0” rated “Sell” for the company. “0” said the company as a “Hold”. Overweight rating was given by “2” and Underweight rating was given by “1”.

Analysts are expecting that the company to achieve $16.30 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $28.00 however minimum price target advised by analysts is $8.00. The Median price target for the stock is measured at $15.50.

Presently, Analysts decided consensus EPS estimate of $-0.81 for present quarter and one month ago projected EPS estimate was at $-0.81. If we take a look at back 3 month ago, consensus EPS estimate was $-0.75.

A current consensus EPS estimate for next quarter is at $-0.83 and 3 month ago EPS forecast was $-0.76. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.83.

For current fiscal year, most recent EPS estimate is set at $-3.21 based on Analyst consensus and three month ago consensus EPS opinions was at $-3.01. During period one month ago, consensus EPS forecast was decided at $-3.21.

A current consensus EPS projection for next fiscal year is observed at $-3.07 and one month ago consensus EPS forecast was at $-2.99. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-2.86 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 5 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 2. 1 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 1.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 5 said a “Buy Rating” and 1 announced “Overweight Rating”. 1 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 1 disclosed “Underweight Rating”.


About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.